The impact of stress on tumor growth: Peripheral CRF mediates tumor-promoting effects of stress

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Arranz, Alicia ^a   Venihaki, Maria ^a   Mol, Berber ^a   Androulidaki, Ariadne ^a   Dermitzaki, Erini ^a   Rassouli, Olga ^a   Ripoll, Jorge ^b   Stathopoulos, Efstathios N ^a   Gomariz, Rosa P ^c   Margioris, Andrew N ^a   Tsatsanis, Christos ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

breast cancer; Corticotropin Releasing Hormonestress4T1

Indexed keywords

ANTALARMIN; BETA CATENIN; CORTICOTROPIN RELEASING FACTOR; LUCIFERASE; SMAD2 PROTEIN; WNT PROTEIN; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BREAST; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHRONIC STRESS; CONTROLLED STUDY; CYTOSKELETON; ENZYME ASSAY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HISTOLOGY; IMMOBILIZATION STRESS; IN VIVO STUDY; MAMMARY GLAND; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; STRESS; TUMOR GROWTH; TUMOR PROMOTION; ANIMAL; BREAST TUMOR; CELL MOTION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CORTICOTROPIN-RELEASING HORMONE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, INBRED BALB C; PYRIMIDINES; PYRROLES; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STRESS, PHYSIOLOGICAL;

EID: 77957162873     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-261     Document Type: Article

References (55)

1. Hasegawa H, Saiki I. Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res 2002, 93:729-735.
2. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004, 5:617-625. 10.1016/S1470-2045(04)01597-9, 15465465.
3. Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN. The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell Mol Life Sci 2007, 64:1638-1655. 10.1007/s00018-007-6555-7, 17453142.
4. Kiank C, Tache Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun 24:41-48. 10.1016/j.bbi.2009.08.006, 19698778.
5. Tache Y, Perdue MH. Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 2004, 16(Suppl 1):137-142. 10.1111/j.1743-3150.2004.00490.x, 15066020.
6. Anton PM, Gay J, Mykoniatis A, Pan A, O'Brien M, Brown D, Karalis K, Pothoulakis C. Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci USA 2004, 101:8503-8508. 10.1073/pnas.0402693101, 420423, 15159534.
7. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA 2004, 101:3697-3702. 10.1073/pnas.0307324101, 373525, 14990799.
8. Nazarloo HP, Buttrick PM, Saadat H, Dunn AJ. The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system. Curr Protein Pept Sci 2006, 7:229-239. 10.2174/138920306777452358, 16787262.
9. Baigent SM. Peripheral corticotropin-releasing hormone and urocortin in the control of the immune response. Peptides 2001, 22:809-820. 10.1016/S0196-9781(01)00395-3, 11337095.
10. Arbiser JL, Karalis K, Viswanathan A, Koike C, Anand-Apte B, Flynn E, Zetter B, Majzoub JA. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 1999, 113:838-842. 10.1046/j.1523-1747.1999.00760.x, 10571742.
11. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004, 44:525-557. 10.1146/annurev.pharmtox.44.101802.121410, 14744257.
12. Kaprara A, Pazaitou-Panayiotou K, Kortsaris A, Chatzaki E. The corticotropin releasing factor system in cancer: expression and pathophysiological implications. Cell Mol Life Sci 2010, 67:1293-306. 10.1007/s00018-010-0265-2, 20143250.
13. Tezval H, Jurk S, Atschekzei F, Becker JU, Jahn O, Serth J, Kuczyk MA. Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation. World J Urol 2009, 27:825-830.
14. Willenberg HS, Haase M, Papewalis C, Schott M, Scherbaum WA, Bornstein SR. Corticotropin-releasing hormone receptor expression on normal and tumorous human adrenocortical cells. Neuroendocrinology 2005, 82:274-281. 10.1159/000093126, 16721033.
15. Graziani G, Ferrandina G, Pozzoli G, Vergati M, Muzi A, Legge F, Tentori L, Scambia G, Navarra P. Corticotropin-releasing hormone receptor-1 in human endometrial cancer. Oncol Rep 2006, 15:375-379.
16. Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 2009, 69:443-448. 10.1002/pros.20892, 19058138.
17. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol 2007, 264:44-49. 10.1016/j.mce.2006.10.006, 17097220.
18. Androulidaki A, Dermitzaki E, Venihaki M, Karagianni E, Rassouli O, Andreakou E, Stournaras C, Margioris AN, Tsatsanis C. Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness. Mol Cancer 2009, 8:30. 10.1186/1476-4598-8-30, 2697132, 19490624.
19. Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, Jeschke U, Paraskevaidis EA, Fountzilas G, Chrousos GP, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer 2007, 97:637-645. 10.1038/sj.bjc.6603918, 2360374, 17667919.
20. Venihaki M, Gravanis A, Margioris AN. Comparative study between normal rat chromaffin and PC12 rat pheochromocytoma cells: production and effects of corticotropin-releasing hormone. Endocrinology 1997, 138:698-704. 10.1210/en.138.2.698, 9003004.
21. Venihaki M, Ain K, Dermitzaki E, Gravanis A, Margioris AN. KAT45, a noradrenergic human pheochromocytoma cell line producing corticotropin-releasing hormone. Endocrinology 1998, 139:713-722. 10.1210/en.139.2.713, 9449645.
22. Sato H, Nagashima Y, Chrousos GP, Ichihashi M, Funasak Y. The expression of corticotropin-releasing hormone in melanoma. Pigment Cell Res 2002, 15:98-103. 10.1034/j.1600-0749.2002.1o063.x, 11936276.
23. Yang Y, Park H, Kim TS, Bang SI, Cho D. Enhancement of cell migration by corticotropin-releasing hormone through ERK1/2 pathway in murine melanoma cell line, B16F10. Exp Dermatol 2007, 16:22-27. 10.1111/j.1600-0625.2006.00511.x, 17181633.
24. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G, Navarra P. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 2002, 143:807-813. 10.1210/en.143.3.807, 11861501.
25. Slominski AT, Roloff B, Zbytek B, Wei ET, Fechner K, Curry J, Wortsman J. Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes. In Vitro Cell Dev Biol Anim 2000, 36:211-216. 10.1290/1071-2690(2000)036<0211:CRHARP>2.0.CO;2, 10777063.
26. Radulovic M, Hippel C, Spiess J. Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem 2003, 84:1074-1085. 10.1046/j.1471-4159.2003.01594.x, 12603831.
27. Wong ML, Webster EL, Spokes H, Phu P, Ehrhart-Bornstein M, Bornstein S, Park CS, Rice KC, Chrousos GP, Licinio J, Gold PW. Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci 1999, 65:PL53-58. 10.1016/S0024-3205(99)00268-4, 10421433.
28. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004, 3:1011-1022. 10.1038/nrd1580, 15573100.
29. Gebeshuber CA, Sladecek S, Grunert S. Beta-catenin/LEF-1 signalling in breast cancer--central players activated by a plethora of inputs. Cells Tissues Organs 2007, 185:51-60. 10.1159/000101303, 17587808.
30. Carlier MF, Pantaloni D. Control of actin assembly dynamics in cell motility. J Biol Chem 2007, 282:23005-23009. 10.1074/jbc.R700020200, 17576764.
31. Tsatsanis C, Androulidaki A, Dermitzaki E, Gravanis A, Margioris AN. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 2007, 210:774-783. 10.1002/jcp.20900, 17117478.
32. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006, 38:1654-1661. 10.1016/j.biocel.2006.03.021, 16713323.
33. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996, 137:5747-5750. 10.1210/en.137.12.5747, 8940412.
34. Agelaki S, Tsatsanis C, Gravanis A, Margioris AN. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun 2002, 70:6068-6074. 10.1128/IAI.70.11.6068-6074.2002, 130344, 12379683.
35. Im E, Rhee SH, Park YS, Fiocchi C, Tache Y, Pothoulakis C. The Corticotropin Releasing Hormone Family of Peptides Regulates Intestinal Angiogenesis. Gastroenterology 2010, 138:2457-67. 10.1053/j.gastro.2010.02.055, 20206175.
36. Saez Mdel C, Barriga C, Garcia JJ, Rodriguez AB, Ortega E. Exercise-induced stress enhances mammary tumor growth in rats: beneficial effect of the hormone melatonin. Mol Cell Biochem 2007, 294:19-24. 10.1007/s11010-005-9067-5, 17136443.
37. Kalantaridou S, Makrigiannakis A, Zoumakis E, Chrousos GP. Peripheral corticotropin-releasing hormone is produced in the immune and reproductive systems: actions, potential roles and clinical implications. Front Biosci 2007, 12:572-580. 10.2741/2083, 17127318.
38. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol 2006, 27:32-39. 10.1016/j.it.2005.10.002, 16269267.
39. Parkes DG, Weisinger RS, May CN. Cardiovascular actions of CRH and urocortin: an update. Peptides 2001, 22:821-827. 10.1016/S0196-9781(01)00396-5, 11337096.
40. van Wijk PA, van Neck JW, Rijnberk A, Croughs RJ, Mol JA. Proliferation of the murine corticotropic tumour cell line AtT20 is affected by hypophysiotrophic hormones, growth factors and glucocorticoids. Mol Cell Endocrinol 1995, 111:13-19. 10.1016/0303-7207(95)03541-E, 7544306.
41. van Wijk PA, Rijnberk A, Croughs RJ, Meij BP, Mol JA. Effects of corticotrophin-releasing hormone, vasopressin and insulin-like growth factor-I on proliferation of and adrenocorticotrophic hormone secretion by canine corticotrophic adenoma cells in vitro. Eur J Endocrinol 1998, 138:309-315. 10.1530/eje.0.1380309, 9539306.
42. Slominski A, Zbytek B, Pisarchik A, Slominski RM, Zmijewski MA, Wortsman J. CRH functions as a growth factor/cytokine in the skin. J Cell Physiol 2006, 206:780-791. 10.1002/jcp.20530, 1351367, 16245303.
43. Gavert N, Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. J Cell Biochem 2007, 102:820-828. 10.1002/jcb.21505, 17854061.
44. Hirota M, Watanabe K, Hamada S, Sun Y, Strizzi L, Mancino M, Nagaoka T, Gonzales M, Seno M, Bianco C, Salomon DS. Smad2 functions as a co-activator of canonical Wnt/beta-catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. Cell Signal 2008, 20:1632-1641. 10.1016/j.cellsig.2008.05.003, 2578836, 18595660.
45. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 2009, 26:273-287. 10.1007/s10585-008-9174-2, 18498004.
46. Cassoni P, Sapino A, Negro F, Bussolati G. Oxytocin inhibits proliferation of human breast cancer cell lines. Virchows Arch 1994, 425:467-472. 10.1007/BF00197549, 7850070.
47. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001, 86:1738-1745. 10.1210/jc.86.4.1738, 11297611.
48. Jeffery PL, Murray RE, Yeh AH, McNamara JF, Duncan RP, Francis GD, Herington AC, Chopin LK. Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr Relat Cancer 2005, 12:839-850. 10.1677/erc.1.00984, 16322325.
49. Wlk M, Wang CC, Venihaki M, Liu J, Zhao D, Anton PM, Mykoniatis A, Pan A, Zacks J, Karalis K, Pothoulakis C. Corticotropin-releasing hormone antagonists possess anti-inflammatory effects in the mouse ileum. Gastroenterology 2002, 123:505-515. 10.1053/gast.2002.34783, 12145804.
50. Webster EL, Barrientos RM, Contoreggi C, Isaac MG, Ligier S, Gabry KE, Chrousos GP, McCarthy EF, Rice KC, Gold PW, Sternberg EM. Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. J Rheumatol 2002, 29:1252-1261.
51. Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 2008, 105:3939-3944. 10.1073/pnas.0712366105, 2268793, 18308934.
52. Wang J, Xu Y, Zhu H, Zhang R, Zhang G, Li S. Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 2008, 26:359-368. 10.1080/07357900701788106, 18443956.
53. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998, 139:403-413. 10.1210/en.139.1.403, 9421440.
54. Arranz A, Androulidaki A, Zacharioudaki V, Martinez C, Margioris AN, Gomariz RP, Tsatsanis C. Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide. Mol Immunol 2008, 45:2970-2980. 10.1016/j.molimm.2008.01.023, 18336909.
55. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V, Margioris AN, Tsichlis PN, Tsatsanis C. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31:220-231. 10.1016/j.immuni.2009.06.024, 2865583, 19699171.